Pegfilgrastim for mobilization of stem cells in allogeneic donors.
Lemoli
Roberto M
RM
Institute of Hematology and Medical Oncology L.&A. Seragnoli, University of Bologna, Italy. rmlemoli@med.unibo.it
D000328:Adult; D000818:Animals; D000069585:Filgrastim; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000494:pharmacology*; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects; D006801:Humans; D016753:Interleukin-10 / Q000378:metabolism; D019520:Living Donors; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D010146:Pain / Q000139:chemically induced; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D013163:Splenomegaly / Q000139:chemically induced; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism; D014184:Transplantation, Homologous / Q000009:adverse effects
D011994:Recombinant Proteins; D016753:Interleukin-10; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim